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ABSTRACT
We reviewed the literature on the use of margins in radiotherapy of patients with prostate cancer, focusing on different
options for image guidance (IG) and technical issues. The search in PubMed database was limited to include studies that
involved external beam radiotherapy of the intact prostate. Post-prostatectomy studies, brachytherapy and particle
therapy were excluded. Each article was characterized according to the IG strategy used: positioning on external marks
using room lasers, bone anatomy and soft tissue match, usage of fiducial markers, electromagnetic tracking and adapted
delivery. A lack of uniformity in margin selection among institutions was evident from the review. In general, introduction
of pre- and in-treatment IG was associated with smaller planning target volume (PTV) margins, but there was a lack of
definitive experimental/clinical studies providing robust information on selection of exact PTV values. In addition, there is
a lack of comparative research regarding the cost–benefit ratio of the different strategies: insertion of fiducial markers or
electromagnetic transponders facilitates prostate gland localization but at a price of invasive procedure; frequent pre-
treatment imaging increases patient in-room time, dose and labour; online plan adaptation should improve radiation
delivery accuracy but requires fast and precise computation. Finally, optimal protocols for quality assurance procedures
need to be established.
INTRODUCTION
Recent advances in radiation therapy (RT) allowed for
more conformal dose delivery to the target and im-
proved sparing of the healthy organs. Higher gradients of
dose distribution require precise determination of the
target position or we can miss the target “precisely”.1,2
This is particularly relevant for prostate cancer RT since
the prostate gland position within the pelvis is likely to
change between treatment fractions.3–5 With increasing
evidence for the benefit of dose escalation and, in par-
allel, an increasing use of sophisticated image guidance
(IG) techniques in RT of prostate cancer, there is a
growing interest to the questions of appropriate margins
for the planning target volume (PTV) and optimization
of IG. The selection of the PTV margin is critical for safe
dose escalation using intensity-modulated RT (IMRT)
with smaller margins permitting higher doses in mod-
elling studies. For example, Goulet et al6 have estimated
the maximum achievable dose to the prostate gland at
83.0, 113.1 and 135.9 Gy for the PTV margins of 10, 5
and 3mm, respectively. In this review, we examine the
range of PTV margins in relation to IG strategies utilized
and discuss various practical approaches to optimization
of image-guided RT (IGRT) for patients with pros-
tate cancer.
METHODS AND MATERIALS
A PubMed search was performed for articles published in
the past 22 years (from December 1992 to March 2016)
using the terms “margin” AND “prostate” AND “radio-
therapy” (686 items) and “margin” AND “prostate” AND
“radiation” (616 items) to identify relevant studies. The
search was limited to studies that involved external beam
treatment of the intact prostate and were published in the
English language. Post-prostatectomy studies, brachyther-
apy and particle beam therapy were excluded. We identified
155 publications.
We categorized each article according to the IG option that
was investigated. Seven key areas of applications were
identified: (1) positioning on external marks using room
lasers (9 references), (2) non-specified IGRT (40 refer-
ences), (3) bone anatomy match (6 references), (4) soft
tissue match (3 references), (5) fiducial markers (28 ref-
erences), (6) electromagnetic tracking (5 references)
and (7) adapted delivery (16 references). Articles that
belonged to one of these seven categories were included
for review. Average values with maximum/minimum
range for the PTV margins proposed in the literature
for different techniques are shown in Figure 1. The values
of recommended PTV margins, employed IG options and




With the introduction of pre-treatment IG, one would expect
that PTV margins could be decreased allowing for better sparing
of the bladder and, especially, of the rectum, organs in very close
proximity to the prostate gland.7 However, the literature data do
not provide a single consensus recipe, and a wide range of PTV
margins from 0 to 20mm were described in the articles
reviewed. Several factors in delivery strategies influence the
proposed margins: (1) imaging before or during radiation de-
livery; (2) the type of imaging device [two-dimensional or three-
dimensional (3D) ultrasound, electronic portal imaging (EPID),
kilovoltage (kV) and megavoltage (MV) cone beam CT (CBCT),
megavoltage fan-beam CT (MVCT), CT on rail]; (3) frequency
of IGRT sessions; (4) a choice of immobilization device, if any;
(5) patient preparation protocol; (6) method of radiation de-
livery [conformal four-field box technique, static IMRT, helical
tomotherapy or volumetric modulated are therapy (VMAT)];
(7) considerations of interobserver target volume delineation
variation; (8) target definition of the prostate only vs prostate
plus seminal vesicles vs inclusion of lymph nodes as well. For
example, Mzenda et al8 considered a model where delineation,
set-up and organ motion-induced errors were included; the
derived margin was on average 0.5mm bigger than currently
used margins in the region of small treatment uncertainties.
How many patients and how often the set-up errors should
be measured to obtain a reliable PTV margin evaluation?
Matsumoto et al9 summarized the data for 35 patients and
used different amounts of position verification and found
that a minimum of 15 patients and .15 verifications
were required.
In another study, PTV margins 8mm (6mm posterior) used in
IMRT plans were considered adequate to deliver a dose to the
prostate with conventional patient positioning using skin tattoos
or bony anatomy while the use of IG allowed for significant PTV
margin reduction to 4mm (3mm posterior) with improved organ-
at-risk (OAR) sparing.10 Similarly, Tsai et al11 recommended a
4.5-mm margin when IGRT-IMRT techniques were employed.
Seminal vesicles are more prone for inter- and intrafraction
motion and require larger PTV margins (e.g. 4.5mm, whereas
3mm for the prostate with online IG12). Inclusion of elective
pelvic lymph nodes in the target volume due to the increased
spatial uncertainly required additional 9-mm in the anterio-
posterior (AP) and 7-mm in the left–right (LR) directions to
account for their daily displacement relative to the prostate.13
Most of the investigations considered translational corrections
only; the impact on target coverage due to prostate rotation was
shown to be almost equal for the PTV margins of 2, 4, 6
and 8mm.14
Nairz et al15 looked for the optimal balance between advan-
tages of a frequent IG and additional cost by a restriction of
daily IGRT. They found that three imaging sessions at the
beginning of the treatment (when uncertainties in the pros-
tate motion and the doctor’s delineation are included in
calculation) required the total PTV margins amounted to
8.6 mm in the LR, 10.4 mm in the superior–inferior (SI) and
14.4mm the AP directions.
Pelvis bone matching is the most common implementation of
IG. In Japan, in a survey of 70 facilities that could perform IGRT,
33 (47.1%) facilities conducted bone matching, 28 (40.0%)
conducted prostate matching and 9 (12.9%) used metal mark-
ers. Prostate or metal marker matching tended to produce a
smaller margin than bone matching.16
Multiple strategies for IG in prostate cancer radiotherapy were
evaluated by Mayyas et al.17 They compared ultrasound, CBCT,
planar kV images and electromagnetic transponders for
27 patients. The use of IG was shown to reduce these margins to
,5mm compared with 10–11mm, when skin tattoos only were
used for guidance with all IGRT strategies providing similar
benefit. Margins to compensate for both residual set-up (inter-
fraction) errors as well as intrafraction motion were 6.6, 6.8 and
3.9mm in the AP, SI and LR directions, respectively.
Alignment of images performed by an operator depends on
his/her experience, training and matching protocol. Deegan
et al18 concluded that in a study of interobserver variability for
alignment of CBCT and planning CT between three radiation
therapists, 95% limits of agreement with the mean were 2mm if
fiducial markers were used for alignment and were 3mm in the
case of soft tissue matching. Zahra et al19 reported a good in-
terobserver reproducibility for CBCT registration. The question
of education for optimal alignment has not been addressed in
the literature.
Thus, while there is variability in the literature with regard to
strategy and recommended PTV margins, the literature would
Figure 1. Average values with maximum/minimum range for
the planning target volume (PTV) margins proposed in
the literature for different techniques: (1) positioning on
external marks using room lasers (9 references), (2) image-
guided radiation therapy (40 references), (3) bone anatomy
match (6 references), (4) soft tissue match (3 references),
(5) fiducial markers (28 references), (6) electromagnetic
tracking (5 references) and (7) adapted delivery (16
references).
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support the use of online IG using either implanted fiducial
markers or soft tissue matching with in-room CTor ultrasound.
With such IG, PTV margins in the range of 6–8mm (3–5mm
posteriorly) were the most commonly reported.
Immobilization options
Immobilization devices may be external or internal and are
employed with the intent of reducing positioning error (external
devices) or prostate motion (internal devices). In one study,
external patient immobilization reduced the calculated clinical
target volume (CTV) to PTV margin to 1.9, 8.3 and 2.3mm for
the Hipfix system (CIVCO Medical Solutions, Kalona, IA) and
3.4, 2.1 and 1.8mm for the whole-body alpha cradle in the LR,
CC and AP axes, respectively.20
The most popular internal immobilization device to reduce
prostate motion is endorectal balloon, and this can serve both as
a localization tool as well as an immobilization tool. The use of
an endorectal balloon was associated with PTV margins of
3–5mm to correct for intrafraction prostate movements.21,22
Other studies23,24 suggested that margins to account for intra-
fraction motion for patients with endorectal balloon were de-
pendent on treatment time, with margins in the 3–5mm range
for treatments under 6min and 4–8mm for treatments beyond
6min in duration.
Others noted that the choice of treatment technique
(four-field box vs four-field box plus IMRT boost vs IMRT
only) was associated with variations in calculated PTV
margins with the use of rectal balloon, with smaller margins
(2–4 mm) calculated for the four-field box technique than
for IMRT techniques (4–6mm).25 Thus, compared with
other forms of IG, the endorectal balloon does not seem to
carry a dramatic benefit in terms of PTV selection when
IMRT delivery is selected, and if such a device is used, efficient
positioning and treatment delivery would seem necessary to re-
alize maximum benefit.
One study examined the use of prostatic calcifications as natural,
internal fiducials for tracking with a kilovoltage X-ray IG system
(ExacTrac® X-ray system; BrainLab Inc., Feldkirchen, Germany).26
In this study, the required PTV margins were found to be 1.4, 9.7
and 6.1mm in the LR, SI and AP directions, respectively.
Although the ability to use intrinsic fiducials is attractive, not
all patients have such calcifications, and the PTV margins seem
larger (6–10mm) than in other IG strategies.
Daily alignment to skin marks
The PTV margins 7.5, 11.4 and 16.3mm were required with
3-point skin mark alignment in the LR, SI and AP directions,
respectively, in a study of 14 patients.27 For the same direc-
tions, Pérez-Romasanta et al28 suggested patient-specific
ranges of the PTV margin values: 9–10.5, 10.6–12.4 and
15.2–17.8mm, respectively. In other studies, 5- to 10-mm
margins (depending on the direction) using skin marks as
reference were proposed with IG, allowing a margin reduction
to 5mm.29,30 Overall, if skin tattoos only are used, the liter-
ature would suggest that generous margins (at least 10mm)
are required.
Use of daily ultrasound
The first reported use of ultrasound for IG for prostate treat-
ment employed a portable ultrasound-based system [B-mode
acquisition and targeting (BAT)] that was shown to provide
prostate localization with the mean absolute magnitude com-
pared with daily CT localizations of 3, 2.4 and 4.6mm in the AP,
LR and SI directions, respectively.31,32 The localization process
where transverse and sagittal suprapubic ultrasound images were
captured, and the system overlaid the corresponding CT con-
tours relative to the machine isocentre, could be completed in
,5min. Daily BAT system localization was compared with
weekly orthogonal portal imaging.33 Prostate internal organ
motion appeared to predominate over set-up error as the major
component of variation in target localization. One concern was
that the BAT procedure itself was found to produce an average
motion of 1mm in the AP and SI directions.34 This effect of
prostate displacement by the ultrasound probe was further in-
vestigated by Artignan et al35 who found that good-quality ul-
trasound images could be achieved by the probe displacement of
about 1.2 cm, and this pressure on the abdomen resulted in an
average prostate displacement of 3.1mm. Large retrospective
analysis of the results of a two-dimensional ultrasound daily pre-
treatment localization revealed a systematic 6.1-mm shift pos-
terior due to differences in planning conditions between the CT
simulation and the treatment room.36 In general, the literature
suggests that 7.5- to 10-mm margins are recommended when
daily ultrasound localization is utilized. Comparison of the
online MV-CBCT and fiducial IG data showed that for treat-
ments that include imaging of fiducial markers or MV-CBCT,
a CTV-to-PTV margin could be 4mm smaller than the one
suggested by ultrasound data.37
Use of daily cross-sectional imaging (fan beam or
cone beam)
Tomotherapy
Zhou et al38 used pre-treatment MVCT-based corrections to
evaluate the required set-up margins for patients with prostate
cancer and reported that accounting for interfraction target
motion required margins of 7.4, 6.6 and 5.4mm in the LR, SI
and AP directions, respectively.
Another study analysed the difference between tomotherapy
MVCT pre- and post-treatment correction shifts to evaluate the
margins required to account for interfraction motion. Margins
of 2.2, 2.1 and 2.1 in the LR, SI and AP directions were required
for translational motion only, and inclusion of the effect of
rotations and matching errors increased these margins to ap-
proximately 4mm in the LR and 5mm in the SI and AP
directions.39 In a similar analysis, larger margins of 11.30, 9.95
and 13.49 mm in the same directions were proposed by
Murthy et al.40
Kilovoltage cone beam CT
Hirose et al41 evaluated dosimetric consequences using kV
CBCT guidance with either 8-mm margins (5-mm margin
posteriorly and superiorly) or 5-mm margins isotropically. They
showed that even with bony set-up correction, the target cov-
erage was sufficient with both margins. They also noted better
sparing of OARs, if the Hipfix immobilization system was used.
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Lerma et al42 demonstrated that with CT IG and online plan-
ning, a 3-mm PTV margin was sufficient. Kim et al43 argued that
the PTV margin should be no ,4mm if daily CBCT imaging is
used for target matching. For the CBCT pre-treatment imaging
used in the first 5 days, the 8-mm PTV margin may not be
enough.44 Similar margins of 7.3, 7.0 and 9.0mm in the LR, SI
and AP directions were proposed for the prostate gland by
quantitative assessment based on CBCT data.45 Target dose
coverage was evaluated by the proportion of the CTV encom-
passed by the 95% isodose for two options of 10- and 7-mm
safety margins by Paluska et al.46 Kliton et al47 suggested 9.3-,
6.5- and 8.9-mm PTV margins in the LR, SI and AP directions if
in-room kV CT is used for IG. The pre-treatment CBCT images
of radio-opaque markers provided information about the mo-
tion of the target immediately preceding the treatment useful for
PTV margin evaluation,48 but no correlation of these data with
pre- and post-CBCT data comparison was found. Normal tissue
complication probability (NTCP) prediction values for late
rectal bleeding of 3.5%, 2.8% and 2.4% were obtained by sim-
ulating three sets of PTV margins: (1) 10 and 6mm at the
prostate/anterior rectal wall interface (10/6mm), (2) 5/3mm
and (3) uniformly 3mm, respectively.49 More elaborate strate-
gies using online CTV translation correction by repeated CT
imaging for confirmation suggested that a 7-mm margin was
sufficient. When the correction of rotation errors was included,
a smaller 4-mm margin was possible.50 Similarly, repeat CT
scans of 19 patients were rigidly aligned with the planning CT
scan using intraprostatic implanted markers, followed by de-
formable registrations; statistical motion models determined
PTV expansions of 5mm.51 Finally, differences in PTV margins
with the use of soft-tissue-based kV CT vs megavoltage guidance
were found with 5-mm margins possible with kV CT.52
On balance, the literature would suggest, with in-room CT
guidance (either fan-beam CTor CBCT), the use of 5- to 8-mm
PTV margins on the gland with 5-mm posterior margins. More
elaborate strategies such as the use of kV CT localization, de-
formable registration and online planning may allow smaller
margins (3–4mm) but at the cost of added time and complexity
for the localization process.
Use of internal fiducials with or without
cross-sectional imaging
Insertion of gold fiducial markers (usually three) in the prostate
gland facilitates visualization of the target position and allows for
smaller PTV margins due to the ability to localize the prostate
on conventional kV portal imaging.18,53,54 In one study, im-
plantation of fiducial markers allowed PTV margin reduction
from 10 to 7mm as verified by reconstruction of dose dis-
tributions after correction using verification CBCT studies.55,56
In another study, set-up margins calculated to encompass 98%
of prostate set-up shifts were 11–14mm with offline corrections
based on alignment to the bone, and the PTV margins needed
were reduced to 4–7mm with the use of online correction using
fiducial markers.57 Similarly, Skarsgard et al58 using set-up to
skin markings without IG noted that margins of 5.7 cm, and 7.9
and 7.7mm, along the LP, and SI and AP axes, respectively, were
required to give 95% probability of complete CTV coverage each
day. Using daily portal images with implanted fiducial markers,
the PTV margins could be reduced to 3.6, 3.7 and 3.7mm,
respectively. Similar margins of 2.69, 3.22 and 3.37mm for the
LR, SI and AP axes using this technique to account for intra-
fraction motion was proposed by Siow et al.59 Graf et al60 in-
vestigated EPID with implanted fiducials using weekly and daily
position correction options: the 7.0-, 9.5- and 9.5-mm PTV
margins in the LR, SI and AP directions (using bone alignment
only) could be lowered, correspondingly, to 6.7, 8.2 and 8.7mm
with weekly correction and down to 4.9, 5.1 and 4.8mm with
daily correction. The same group reported that usage of kV
X-rays for more precise position correction lowered the margins
calculated in the LR, SI and AP directions from 2.3, 3.7 and
3.0mm to 1.8, 1.8 and 2.1mm if a second repositioning was
applied.61
Seo et al62 noted that a margin of 4.97mm around the CTV
provided adequate coverage when two oblique kV images were
used for bone alignment corrected by the position of fiducial
markers. The results of the NTCP modelling by Gauthier et al63
suggest that the reduction in the PTV margin from 15mm
(10mm posteriorly) to 10mm (6mm posteriorly) afforded by
kV fiducial marker localization should decrease the rate of late
rectal toxicities and allow moderate dose escalation. Clinically,
Engels et al64 reported on conformal arc therapy in treatment of
213 patients with prostate cancer without implanted markers,
with 6-mm LR and 10-mm SI and AP margins and compared
with clinical results for 25 patients treated with fiducial markers
with 3-mm LR and 5-mm SI and AP margins. They noted
similar rectal toxicity in-between two cohorts. Shimizu et al65
reported on 110 patients treated with real-time tracking of fi-
ducial markers and a PTV margin of 3mm. They noted low
adverse events with favourable relapse-free survival suggesting that
the small margins did not compromise prostate coverage with their
localization protocol. Other reports of localization with fiducials by
continuous tracking allowed a 3-mm margin instead of 5-mm
margin, without a significant compromise in dose.66 In addition to
real-time tracking correction for rotations as well as translation can
improve accuracy.67 Fiducial markers tracking, combined with
a possibility to adjust patient position in six dimensions using
ExacTrac/Novalis Body™ (ET/NB) System and a robotic couch,
allowed for smaller PTV margins of 2.9 and 2.8mm in the SI and
AR directions.68
Unlike localization of the prostate, inclusion of the seminal
vesicles can still be problematic. For example, a margin of 8mm
was found insufficient for seminal vesicles owing to deformations
even in the case of continuous fiducial markers tracking, whereas
5-mm PTV margin for the prostate provided sufficient dosimetric
coverage.69 Likewise, others noted that a margin of 8.2mm for the
seminal vesicles was necessary, even if daily marker-based rotation
correction of the seminal vesicles is performed.70
The use of fiducial markers is attractive given the relative ease
of localization on a variety of imaging platforms (EPID, kV
imaging, CBCT). The literature would suggest that margin
reductions to 5mm are possible with the use of implanted
fiducials with possible further reductions to 3mm if sophisti-
cated fiducial marker strategies are used such as incorporation of
rotation correction or real-time tracking.
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Optimizing image guidance strategies
Frequency of imaging/repeat
cross-sectional imaging
Given the time required for daily localization, exploration of
alternative imaging schedules has been investigated. For example,
Yan et al71 investigated an offline adaptive planning process and
noted no advantage to 2 weeks of daily CT in constructing a custom
PTV margin compared with imaging during the first week for the
conventional beam delivery. Nairz et al15 looked for the optimal
balance between advantages of a frequent IG and additional cost.
They found that three imaging sessions at the beginning of the
treatment resulted in total PTV margins of 8.6mm in the LR,
10.4mm in the SI and 14.4mm in the AP directions, suggesting
that more frequent imaging may be necessary to reduce margins.
Bortfeld et al72 found a simple formula for the optimum number n
of measurements of patient positions during the first n treatment
fractions (n5 4 for typical cases) followed by patient position of
new external marks without imaging and integrated this principle
into a “no action level” protocol. This idea was used in the analysis
of daily position corrections by pre-treatment MVCT imaging for
patients with prostate cancer and simulation of the residual errors if
the no-action-level protocol was applied.73,74 The adaptive pro-
cedure based on the online set-up correction enabled Piziorska
et al75 to reduce the PTV margin to 7, 7 and 4mm for the vertical,
longitudinal and lateral directions, respectively.
While tracking the intrafraction motion with the Calypso system
(Varian, Palo Alto, CA), smaller margins require more frequent
imaging to achieve adequate geometric target coverage.76
Accounting for interobserver and
intermachine variability
Image-guided therapy QA center recalculated the registration
shifts using three independent software systems [MIMvista,
(MIM Software Inc. Cleveland, OH), FocalSim (CMS Inc., St
Louis, MO) and VelocityAI (Velocity Medical Solutions, Atlanta,
GA)] and compared these with the data sent from three IG
systems: Tomotherapy Hi-ART (Accuray Inc., Sunnyvale, CA),
Synergy (Elekta, Crawley, UK) and Trilogy (Varian, Palo Alto,
CA).77 For the 66 comparisons in prostate cases, the differences
of 1.16 1.0, 2.16 1.7 and 2.06 1.8mm in the LR, SI and AP
directions, respectively, were found. Quality assurance of the
image registration process with a phantom is needed before
considering margin reduction using IGRT.
Patient-specific margins and adapted radiotherapy
Non-representative patient anatomy (distended rectum or bladder)
at the time of planning may require larger PTV margins to account
for systematic error while on treatment. For example, more gen-
erous margins were needed for patients with the combination of
rectal volume .60 cm3 and bladder volumes .40 cm3 from the
study of prostate displacement observed by CTs before, during and
after radiotherapy.78 Likewise, patients with large rectum and
bladder volumes required larger margins in a cohort of 213 patients
without implanted markers (6-mm LR and 10-mm SI and AP
margins) and in a cohort of 25 patients in whom implanted
markers were used for positioning (3-mm LR and 5-mm SI and AP
margins).64 Similarly, larger body habitus, as measured body mass
index (BMI) of the patient may lead to more set-up uncertainty,
requiring either larger PTV margins or more frequent imaging.
For example, one study demonstrated benefits to daily imaging
for obese and overweight patients (BMI.25), whereas the patients
with normal BMI could be treated with imaging guidance restricted
to the first few initial treatment fractions with calculated patient-
specific set-up corrections applied thereafter.79
Schulze et al80 evaluated the possible effect of online daily replanning
and estimated better organ-at-risk sparing: the rectum and bladder
doses were lower by 11% and 14%, respectively. With CBCT pre-
treatment imaging, matching based on bony anatomy, soft tissue
and online reoptimization was evaluated using the 10- and 5-mm
PTV margins.81 Dose calculation cumulated .40 fractions revealed
a drop in minimum dose to the prostate of approximately 8%
between a 5-mm and 3-mm PTV margin plan.66
A review of image-guided adaptive techniques included discus-
sion of online replanning through direct beam aperture modi-
fication for conformal radiotherapy, multileaf collimator
segment adjustment for IMRT, online inverse planning, hybrid
online correction or offline replanning and full online adaptive
inverse planning.82 Replanning of the dose delivery based on the
data from CT-on-rail technology allowed for PTV margin re-
duction from 5mm (3mm towards rectum) to 2mm.83
The adaptive strategy based on the five first fractions resulted in
margins ranging from 1 to 3.2 mm in the RL, 2–6.6mm in the SI
and 2–7mm in the AP directions depending on the patient,
whereas population margins to include the same percentage of
motion were 1.7, 4.1 and 4.0mm.84 Therefore, population-based
approach results in overdosing of some of the patients and in
underdosing of the others. Offline adaptive dose compensation
technique could effectively reduce the required margin by
1–2mm compared with online IG-only strategy.85,86 The online
aperture adaptation allowed safe reduction of PTV margins down
to 5mm when only interfractional corrections were applied.87
Given the time required for adaptive replanning using current
platforms, the generation of patient-specific margins and/or
imaging schedules based on analysis of early treatment imaging
histories and/or measurements of patient-specific factors such as
BMI and rectal and bladder volumes may be more practical
strategies. Such strategies may allow a reduction in imaging
frequency and/or PTV margins. In an exploration of the dosi-
metric consequences of various adaptive and imaging strategies,
Battista et al88 noted that one offline replanning using person-
alized margins calculated from images acquired during the first
6 days of a 7-week radiation schedule yielded the best OAR
sparing without compromising target volume coverage.
Accounting for intrafraction motion
Prostate gland motion during radiation treatment itself adds an
uncertainty for the target location that requires addition of
“intrafraction motion” margin. Taking into account prostate
gland motion during treatment presents a significant challenge.
Several techniques were reported: continuous EPID,89 CBCT
before and after treatment,90 and electromagnetic tracking
system.27,91–95 Kupelian et al91 using electromagnetic tracking
Review article: Target margins in radiotherapy of prostate cancer BJR
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(single responder) with Calypso system showed that intra-
fraction motion was not only strongly patient dependent but
also changed between treatment fractions. The same approach
made it possible to determine anisotropic character of intra-
fraction motion leading to margins for the LR, SI and AP axes of
8.4, 10.8 and 14.7mm for skin mark-only set-up and 1.3, 2.3
and 2.8mm using the online set-up correction.93
Margins of 6mm were needed to compensate for intrafraction
motion when this was estimated from pre- and post-radiation
CBCT.90 Rassiah-Szegedi et al94 showed that individualized
margin design based on the data obtained from electromagnetic
transponders can provide better OAR sparing than conventional
7-mm or even 5-mm uniform margins. A 3-mm margin at the
prostate–rectal interface and 5mm elsewhere was recommended
if electromagnetic tracking is used for VMAT treatment.95 A
larger 8-mm uniform PTV margin was proposed by Budiharto
et al96 for online IMRT adjustment with IG between gantry angle
changes. Kurosawa et al97 evaluated that 4.73-mm PTV margin is
sufficient to account for intrafractional set-up and organ motion.
With real-time couch adjustment and real-time tracking to account
for intrafraction motion, Li et al92 estimated the necessary posterior
margin of 6.4 and 4.6mm (the latter with prostate rotation cor-
rection) compared with 7.5 and 7.2mm for 5- and 3-mm threshold
gated treatments. These margins were relatively large because other
uncertainties (target delineation, immobilization device and beam
delivery errors) were included in these calculations. The longer the
treatment, the more pronounced the effect of intrafraction motion,
and they noted a 3-mm internal margin may sufficiently account
for 95% of intrafraction prostate movement for up to 6min of
treatment time if endorectal balloon and fiducial markers are used
for prostate immobilization and localization.27
The intrafraction motion pattern has been shown to differ be-
tween patients and even in different fractions for the same
treatment course.91 Intratreatment motion has been evaluated
by imaging before and after radiation delivery39,48,90,98–100 or
directly during treatment using implanted electromagnetic
transponders (beacons).20,101,102 Fluoroscopy can also be used
for prostate tracking at the expense of increased imaging dose,
but Crocker et al103 argued that this dose could be significantly
reduced if the imaging field size is tailored to specific patients.
Margin requirements accounting for intrafraction motion were
evaluated by Tanyi et al27 for different localization techniques:
1.4, 2.6 and 2.3mm for implanted electromagnetic transponder
detection; 2.1, 9.4 and 10.5mm for volumetric imaging with
bony landmark registration; and 2.8, 3.7 and 3.2mm for volu-
metric imaging with implanted fiducial marker registration in
the LR, SI and AP directions, respectively. Introduction of
hypofractionated stereotactic body radiotherapy to treat prostate
cancer and rotational techniques for delivery presented addi-
tional challenges for OARs sparing, and Tree et al104 evaluated
the need of a 5-mm isotropic margin, except 3mm posteriorly,
aiming to deliver 47.5 Gy in five fractions to the boost whilst
treating the whole prostate to 36.25Gy in five fractions using
RapidArc (Varian). This margin is possible if intrafraction
tracking is implemented, otherwise an 8-mm isotropic margin,
except 5mm posteriorly, is required with more OAR toxicity.
Thus, the literature would suggest that real-time tracking to
correct for intrafraction motion may yield benefits in terms of
reduction of PTV margins to the range of 3–4mm compared
with 5–8mm for image localization without tracking. The
benefits of this margin reduction of 1–2mm need to be con-
sidered against the need for invasive markers required for such
real-time tracking.
Margin calculations
Most publications use “van Herk” equation for the PTV margin
that provides a minimum 95% of the prescription dose to the
CTV for 90% of patients calculated as 2.5 +1 0.7s.105,106 The
2.5 + component accounts for the systematic errors. A further
margin of 0.7s is added to account for random set-up and
organ-motion uncertainties during treatment. Owing mainly
to its simplicity, this equation has been universally used in
spite of various proposed modifications: McKenzie et al107
presented a table of the required random error component of
the margin depending on the number of beams; Witte et al108
used an analytic model to show that the random error margin
increased with tissue density and decreased with target size, leading
to significant changes in the minimummargin required for random
errors. There were attempts to include radiobiology considerations
in margin calculations by Witte et al109 and Mzenda et al.110 Other
models for random errors have been considered by Herschtal
et al111 who looked for the optimal statistical model to account for
random errors and by Suzuki et al112 who assumed a non-Gaussian
distribution. Also, the original caution113 that 2.5 +1 0.7s margin
excludes rotational errors and shape deviations and must be con-
sidered as a lower limit for safe radiotherapy has been generally
ignored. In principle, + and s should include other uncertainties
and be calculated as quadratic sums of errors in target delineation,
inter- and intrafraction translation and rotation motion; errors in
localization device; and errors in beam delivery system.114,115
Instead of specifying a “hard margin”, Li and Xing116 described an
inverse planning algorithm which takes into consideration posi-
tional uncertainty in terms of spatial probability distribution. Witte
et al109 proposed a probabilistic planning method with biological
cost functions that does not require the definition of margins. A
target probabilistic planning approach that defines safety margins
by directly including the effect of geometric uncertainty into the
evaluation of objective functions during optimization was further
developed by Bohoslavsky et al.117 This approach resulted in more
regular isodoses and in reduced dose, on average, to OARs, up to
.6Gy, while maintaining target coverage and keeping the maxi-
mum dose to limiting structures within requirements. Using cus-
tom software plugins in a commercial treatment planning system,
Fontanarosa et al118 evaluated this method by replanning three
prostate cases’ probabilistic objective functions and found that the
new plans achieved similar or better dose distributions than the
original clinical plans in terms of expected target coverage and
rectum wall sparing. A probabilistic treatment planning was shown
to improve conformality and decrease “dosimetric”margin defined
as the specific isodose line compared with standard plan.119–122
Barriers to implementing such probabilistic planning techniques
include incorporating such algorithms into commercial treatment
planning platforms, determination of accurate input parameters
into such algorithms (also necessary for traditional margin
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calculation “recipes”) and validation of the safety and efficacy of
such plans in clinical cohorts.
Impact of image guidance in prostate cancer
Clinical outcomes
The ultimate reason for using more sophisticated (and more
expensive) technology is improvement of patients’ health. Prior
to the introduction of relatively cheap ultrasound devices for
localization of the prostate and seminal vesicles, relatively large
(1.5-cm) anterior and lateral safety margins along with a poste-
rior margin encompassing the anterior one third of the rectal
circumference contributed to rectal toxicity that decreased with
the use of tighter margins afforded by ultrasound localization.123
3D ultrasound was tested for two groups of patients treated with
5- or 10-mm margin with conclusion that margin size had no
impact either on biochemical control or on late toxicity.124 Good
outcomes were achieved by Patel et al125 by using a uniform
7-mm margin and daily ultrasound IGRT. Electromagnetic
real-time tracking combined with 3-mm PTV margins led to
less radiotherapy-related morbidity.126
Toxicity in patients with prostate cancer treated to 78Gy, based on
daily IG of fiducial markers and 5- to 7-mm PTV margins, was less
than in those treated to 76Gy with 3D conformal radiation therapy
and 1- to 2-cm PTV margins.127 Biochemical failure occurred in
13.6% of 140 patients treated with 1-cm PTV margin with late
grade 3 genitourinary and gastrointestinal toxicity rates in 1.6%
and 3% of patients, respectively.128 No obvious detriment using the
smaller radiotherapy margin of 1 cm instead of 1.5 cm was ob-
served in a clinical trial including 126 patients treated with 3D
CRT.129 At median follow-up of 23 months, biochemical relapse-
free survival rate was 95.2%, and only one patient required pre-
mature conclusion at 45Gy due to grade 3 genitourinary toxicity in
hypofractionated treatment on tomotherapy with the PTV margins
of 11.30, 9.95 and 13.49mm in the LR, SI and AP directions,
respectively.40 Likewise, Kupelian et al130 reported on a large cohort
(n5 488) of males with prostate cancer treated with moderately
hypofractionated radiotherapy (70Gy/28 fractions) using daily ul-
trasound guidance. They noted low rates of toxicity and high rates
of biochemical control. They also noted an independence of their
results from the rectal volume at the time of CT planning, sug-
gesting that daily IG offset the systematic errors introduced by
extremes of anatomy at the time of simulation.
Cost/benefit ratio of new technology in
prostate cancer
Many factors should be taken in assessment of potential benefits in
introduction of sophisticated new technology. Improved patients’
quality of life will be reflected in better patient performance in his/
her workplace. Reduced acute and late toxicity will result in less
expense for follow-up medical care and drugs. 19 years ago, Perez
et al131 predicted an overall benefit of 3D conformal radiotherapy
in treatment of localized prostate cancer due to better local
tumour control and decreased treatment morbidity in spite of
increased initial reimbursement for introduction of conformal
radiotherapy (28% higher than standard radiotherapy and 12%
higher than radical prostatectomy). Introduction of IG is still
under investigation from the economy point of view. Ploquin
and Dunscombe132 argued that IG used solely for translational
patient repositioning for prostate cancer adds costs with rela-
tively little improvement in dosimetric quality. However, full
exploitation of the potential of IGRT, particularly through
margin reduction, can be expected to result in a reduction in
the cost–outcome ratios. Recent clinical series suggest benefits
of the addition of IG to either 3D conformal radiotherapy or
IMRT.133
CONCLUSION
Our approach to the choice of appropriate PTV margin in
RT of patients with prostate cancer is still far from being
uniform in different institutions. Although everyone feels
that an introduction of pre- and in-treatment IG should
allow for tighter margins with improved OARs sparing, the
exact values are on a research/discussion stage, and the
experimental/clinical studies providing robust information
on this subject are scarce. And always there is a question
of the optimal balance: insertion of fiducial markers or
electromagnetic transponders facilitate prostate gland local-
ization but at a price of invasive procedure; frequent pre-
treatment imaging increases patient in-room time, dose and
labour; online plan adaptation should improve radiation
delivery accuracy but requires fast and precise computation.
The role and protocols for quality assurance procedures
should be established. Careful analysis of clinical outcomes
with respect to employed PTV margins and including
patient-specific data could lead to personalized choice for
optimal treatment of prostate cancer. In general, the litera-
ture would support PTV margins of 10 mm or more when
using set-up based on alignment to skin marks or bony
anatomy; PTV margins of 5–8mm when using daily cross-
sectional imaging based on soft-tissue registration or when
using implanted fiducial markers; and PTV margins of 3-mm
when using highly sophisticated techniques such as rapid
delivery coupled with real-time tracking, adaptive replanning
or protocols that incorporate corrections for rotations as well
as translations.
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Pilichowska M, Pęczkowski P. Adaptive off-
line protocol for prostate external radio-
therapy with cone beam computer tomog-
raphy. Strahlenther Onkol 2012; 188:
1003–9. doi: http://dx.doi.org/10.1007/
s00066-012-0226-9
76. Curtis W, Khan M, Magnelli A, Stephans K,
Tendulkar R, Xia P. Relationship of imaging
frequency and planning margin to account
for intrafraction prostate motion: analysis
based on real-time monitoring data. Int J
Radiat Oncol Biol Phys 2013; 85: 700–6. doi:
http://dx.doi.org/10.1016/j.
ijrobp.2012.05.044
77. Cui Y, Galvin JM, Straube WL, Bosch WR,
Purdy JA, Li XA, et al. Multi-system
verification of registrations for image-
guided radiotherapy in clinical trials. Int J
Radiat Oncol Biol Phys 2011; 81: 305–12.
doi: http://dx.doi.org/10.1016/j.
ijrobp.2010.11.019
78. Zelefsky MJ, Crean D, Mageras GS, Lyass O,
Happersett L, Ling CC, et al. Quantification
and predictors of prostate position vari-
ability in 50 patients evaluated with mul-
tiple CT scans during conformal
radiotherapy. Radiother Oncol 1999; 50:
225–34. doi: http://dx.doi.org/10.1016/
S0167-8140(99)00011-0
79. Piotrowski T, Kaczmarek Jodda A,
Ryczkowski A, Bajon T, Rodrigues G,
Yartsev S. Image guidance procedures in
radiotherapy for prostate cancer and the
influence of BMI. J Radiother Pract 2014;
13: 410–17. doi: http://dx.doi.org/10.1017/
S1460396914000193
80. Schulze D, Liang J, Yan D, Zhang T.
Comparison of various online IGRT strat-
egies: The benefits of online treatment plan
re-optimization. Radiother Oncol 2009; 90:
367–76. doi: http://dx.doi.org/10.1016/j.
radonc.2008.08.012
81. Thongphiew D, Wu QJ, Lee WR, Chankong
V, Yoo S, McMahon R, et al. Comparison of
online IGRT techniques for prostate IMRT
treatment: adaptive vs repositioning cor-
rection. Med Phys 2009; 36: 1651–62. doi:
http://dx.doi.org/10.1118/1.3095767
82. Ghilezan M, Yan D, Martinez A. Adaptive
radiation therapy for prostate cancer. Semin
Radiat Oncol 2010; 20: 130–7. doi: http://dx.
doi.org/10.1016/j.semradonc.2009.11.007
83. Ahunbay EE, Peng C, Holmes S, Godley A,
Lawton C, Li XA. Online adaptive replan-
ning method for prostate radiotherapy. Int J
Radiat Oncol Biol Phys 2010; 77: 1561–72.
doi: http://dx.doi.org/10.1016/j.
ijrobp.2009.10.013
84. Adamson J, Wu Q. Prostate intrafraction
motion assessed by simultaneous kV fluo-
roscopy at MV delivery II: adaptive strat-
egies. Int J Radiat Oncol Biol Phys 2010; 78:
1323–30. doi: http://dx.doi.org/10.1016/j.
ijrobp.2009.09.079
85. Liu H, Wu Q. Dosimetric and geometric
evaluation of a hybrid strategy of offline
adaptive planning and online image guid-
ance for prostate cancer radiotherapy. Phys
Med Biol 2011; 56: 5045–62. doi: http://dx.
doi.org/10.1088/0031-9155/56/15/024
86. Liu H, Wu Q. Evaluations of an adaptive
planning technique incorporating dose
BJR Yartsev and Bauman
10 of 12 birpublications.org/bjr Br J Radiol;89:20160312
feedback in image-guided radiotherapy of
prostate cancer. Med Phys 2011; 38:
6362–70. doi: http://dx.doi.org/10.1118/
1.3658567
87. Deutschmann H, Kametriser G, Steininger
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89. Månsson Haskå T, Honore H, Muren LP,
Høyer M, Poulsen PR. Intrafraction
changes of prostate position and geomet-
rical errors studied by continuous elec-
tronic portal imaging. Acta Oncol 2008; 47:
1351–7. doi: http://dx.doi.org/10.1080/
02841860802256509
90. Polat B, Guenther I, Wilbert J, Goebel J,
Sweeney RA, Flentje M, et al. Intra-
fractional uncertainties in image-guided
intensity-modulated radiotherapy (IMRT)
of prostate cancer. Strahlenther Onkol 2008;
184: 668–73. doi: http://dx.doi.org/
10.1007/s00066-008-1875-6
91. Kupelian P, Willoughby T, Mahadevan A,
Djemil T, Weinstein G, Jani S, et al. Multi-
institutional clinical experience with the
calypso system in localization and contin-
uous, real-time monitoring of the prostate
gland during external radiotherapy. Int J
Radiat Oncol Biol Phys 2007; 67: 1088–98.
doi: http://dx.doi.org/10.1016/j.
ijrobp.2006.10.026
92. Li JS, Jin L, Pollack A, Horwitz EM,
Buyyounouski MK, Price RA Jr, et al. Gains
from real-time tracking of prostate motion
during external beam radiation therapy. Int
J Radiat Oncol Biol Phys 2009; 75: 1613–20.
doi: http://dx.doi.org/10.1016/j.
ijrobp.2009.05.022
93. Su Z, Zhang L, Murphy M, Williamson J.
Analysis of prostate patient setup and
tracking data: potential intervention strat-
egies. Int J Radiat Oncol Biol Phys 2011; 81:
880–7. doi: http://dx.doi.org/10.1016/j.
ijrobp.2010.07.1978
94. Rassiah-Szegedi P, Wang B, Szegedi M,
Tward J, Zhao H, Huang YJ, et al. In-
dividualized margins for prostate patients
using a wireless localization and tracking
system. J Appl Clin Med Phys 2011; 12: 3516.
95. Zhang P, Mah D, Happersett L, Cox B,
Hunt M, Mageras G. Determination of
action thresholds for electromagnetic
tracking system-guided hypofractionated
prostate radiotherapy using volumetric
modulated arc therapy. Med Phys 2011;
38: 4001–8. doi: http://dx.doi.org/
10.1118/1.3596776
96. Budiharto T, Slagmolen P, Haustermans K,
Maes F, Junius S, Verstraete J, et al. Intra-
fractional prostate motion during online
image guided intensity-modulated radio-
therapy for prostate cancer. Radiother Oncol
2011; 98: 181–6. doi: http://dx.doi.org/
10.1016/j.radonc.2010.12.019
97. Kurosawa Y, Ishikawa H, Hoshino Y,
Higuchi H, Ogano T, Kawamura H, et al.
Intra-fractional set-up and organ motion
errors in intensity-modulated radiation
therapy for prostate cancer. Nihon Hoshasen
Gijutsu Gakkai Zasshi 2012; 68: 290–8. doi:
http://dx.doi.org/10.6009/jjrt.2012_
JSRT_68.3.290
98. Drabik DM, MacKenzie MA, Fallone GB.
Quantifying appropriate PTV setup mar-
gins: analysis of patient setup fidelity and
intrafraction motion using post-treatment
megavoltage computed tomography scans.
Int J Radiat Oncol Biol Phys 2007; 68:
1222–8. doi: http://dx.doi.org/10.1016/j.
ijrobp.2007.04.007
99. Kron T, Thomas J, Fox C, Thompson A,
Owen R, Herschtal A, et al. Intra-fraction
prostate displacement in radiotherapy esti-
mated from pre- and post-treatment im-
aging of patients with implanted fiducial
markers. Radiother Oncol 2010; 95: 191–7.
doi: http://dx.doi.org/10.1016/j.
radonc.2010.01.010
100. Iwama K, Yamazaki H, Nishimura T, Oota
Y, Aibe H, Nakamura S, et al. Analysis of
intrafractional organ motion for patients
with prostate cancer using soft tissue
matching image-guided intensity-
modulated radiation therapy by helical
tomotherapy. Anticancer Res 2013;
33: 5675–9.
101. Willoughby TR, Kupelian PA, Pouliot J,
Shinohara K, Aubin M, Roach M, et al.
Target localization and real-time tracking
using the calypso 4D localization system in
patients with localized prostate cancer. Int J
Radiat Oncol Biol Phys 2006; 65: 528–34.
doi: http://dx.doi.org/10.1016/j.
ijrobp.2006.01.050
102. Li HS, Chetty IJ, Enke CA, Foster RD,
Willoughby TR, Kupellian PA, et al. Dosi-
metric consequences of intrafraction pros-
tate motion. Int J Radiat Oncol Biol Phys
2008; 71: 801–12. doi: http://dx.doi.org/
10.1016/j.ijrobp.2007.10.049
103. Crocker JK, Ng JA, Keall PJ, Booth JT.
Measurement of patient imaging dose for
real-time kilovoltage X-ray intrafraction
tumour position monitoring in prostate
patients. Phys Med Biol 2012; 57: 2969–80.
doi: http://dx.doi.org/10.1088/0031-9155/
57/10/2969
104. Tree A, Jones C, Sohaib A, Khoo V, van As
N. Prostate stereotactic body radiotherapy
with simultaneous integrated boost: which
is the best planning method? Radiat Oncol
2013; 8: 228. doi: http://dx.doi.org/10.1186/
1748-717X-8-228
105. van Herk M, Remeijer P, Rasch C. The
probability of correct target dosage: dose-
population histograms for deriving treat-
ment margins in radiotherapy. Int J Radiat
Oncol Biol Phys 2000; 47: 1121–35. doi:
http://dx.doi.org/10.1016/S0360-3016(00)
00518-6
106. Stroom JC, Koper PC, Korevaar GA. In-
ternal organ motion in prostate cancer
patients treated in prone and supine
treatment position. Radiother Oncol 1999;
51: 237–48. doi: http://dx.doi.org/10.1016/
S0167-8140(99)00061-4
107. McKenzie AL, van Herk M, Mijnheer B.
The width of margins in radiotherapy
treatment plans. Phys Med Biol 2000;
45: 3331–42.
108. Witte MG, van der Geer J, Schneider C,
Lebesque JV, van Herk M. The effects of
target size and tissue density on the
minimum margin required for random
errors. Med Phys 2004; 31: 3068–7. doi:
http://dx.doi.org/10.1118/1.1809991
109. Witte MG, van der Geer J, Schneider C,
Lebesque JV, Alber M, van Herk M. IMRT
optimization including random and sys-
tematic geometric errors based on the
expectation of TCP and NTCP. Med Phys
2007; 34: 3544–559. doi: http://dx.doi.org/
10.1118/1.2760027
110. Mzenda B, Hosseini-Ashrafi M, Gegov A,
Brown DJ. A fuzzy convolution model for
radiobiologically optimized radiotherapy
margins. Phys Med Biol 2010; 55: 3219–35.
doi: http://dx.doi.org/10.1088/0031-9155/
55/11/015
111. Herschtal A, Foroudi F, Greer PB, Eade TN,
Hindson BR, Kron T. Finding the optimal
statistical model to describe target motion
during radiotherapy delivery—a Bayesian
approach. Phys Med Biol 2012; 57: 2743–55.
doi: http://dx.doi.org/10.1088/0031-9155/
57/9/2743
112. Suzuki J, Tateoka K, Shima K, Yaegashi Y,
Fujimoto K, Saitoh Y, et al. Uncertainty in
patient set-up margin analysis in radiation
Review article: Target margins in radiotherapy of prostate cancer BJR
11 of 12 birpublications.org/bjr Br J Radiol;89:20160312
therapy. J Radiat Res 2012; 53: 615–19. doi:
http://dx.doi.org/10.1093/jrr/rrs003
113. van Herk M, Remeijer P, Rasch C, Lebesque
JV. The probability of correct target dosage:
dose-population histograms for deriving
treatment margins in radiotherapy. Int J
Radiat Oncol Biol Phys 2000; 47: 1121–35.
doi: http://dx.doi.org/10.1016/S0360-3016
(00)00518-6
114. Bidmead M, Coffey M, Crellin A, Dobbs J,
Driver D, Greener T, et al, eds. Geometric
uncertainties in radiotherapy: defining the
planning target volume. London, UK: Brit-
ish Institute of Radiology; 2003.
115. Wilkinson JM. Geometric uncertainties in
radiotherapy. Br J Radiol 2004; 77: 86–7.
doi: http://dx.doi.org/10.1259/bjr/25924254
116. Li JG, Xing L. Inverse planning incorpo-
rating organ motion. Med Phys 2000; 27:
1573–8. doi: http://dx.doi.org/10.1118/
1.599023
117. Bohoslavsky R, Witte MG, Janssen TM, van
Herk M. Probabilistic objective functions
for margin-less IMRT planning. Phys Med
Biol 2013; 58: 3563–80. doi: http://dx.doi.
org/10.1088/0031-9155/58/11/3563
118. Fontanarosa D, van der Laan HP, Witte M,
Shakirin G, Roelofs E, Langendijk JA, et al.
An in silico comparison between margin-
based and probabilistic target-planning
approaches in head and neck cancer
patients. Radiother Oncol 2013; 109: 404–8.
doi: http://dx.doi.org/10.1016/j.
radonc.2013.07.012
119. Gordon JJ, Siebers JV. Coverage-based
treatment planning: optimizing the IMRT
PTV to meet a CTV coverage criterion.
Med Phys 2009; 36: 961–73. doi: http://dx.
doi.org/10.1118/1.3075772
120. Moore JA, Gordon JJ, Anscher MS, Siebers
JV. Comparisons of treatment optimization
directly incorporating random patient
setup uncertainty with a margin-based
approach.Med Phys 2009; 36: 3880–90. doi:
http://dx.doi.org/10.1118/1.3176940
121. Moore JA, Gordon JJ, Anscher M, Silva J,
Siebers JV. Comparisons of treatment
optimization directly incorporating
systematic patient setup uncertainty with
a margin-based approach. Med Phys 2012;
39: 1102–11. doi: http://dx.doi.org/10.1118/
1.3679856
122. Xu H, Vile DJ, Sharma M, Gordon JJ,
Siebers JV. Coverage-based treatment
planning to accommodate deformable or-
gan variations in prostate cancer treatment.
Med Phys 2014; 41: 101705. doi: http://dx.
doi.org/10.1118/1.4894701
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